Document is current
Any future updates will be listed below
-
Authors
Palou-Márquez, Guillermo
Subirana, Isaac
Nonell, Lara
Fernández-Sanlés, Alba
Elosua, Roberto https://orcid.org/0000-0001-8235-0095
-
Funding
Funding for this research was provided by:
Instituto de Salud Carlos III (FIS P18/00017, CIBERCV, CIBERESP)
Agència de Gestió d’Ajuts Universitaris i de Recerca (SLT002/16/00088, 2017SGR946)
Ministerio de Economía, Industria y Competitividad, Gobierno de España (BES-2014-069718)
National Heart, Lung, and Blood Institute (N01-HC-25195, HHSN2682015000001)
- License Information
-
More Information
Article History
Received: 8 January 2021
Accepted: 29 March 2021
First Online: 9 April 2021
Declarations
:
: FOS data were obtained through the database of Genotypes and Phenotypes (dbGAP, ; project number #9047). The study was approved by the Parc Salut Mar ethics committee (2015/6199/I; 2018/7855/I) and meets the principles expressed in the Declaration of Helsinki and the relevant European legislation.
: Not applicable.
: The authors declare that they have no competing interests. The Framingham Heart Study (FHS) is conducted and supported by the US National Heart, Lung and Blood Institute (NHLBI) in collaboration with Boston University (Contract No. N01-HC-25195 and HHSN268201500001I). This manuscript was not prepared in collaboration with investigators of the FHS, has not been reviewed and/or approved by the FHS and does not necessarily reflect the opinions or views of the FHS investigators or the NHLBI.
